High‐dose supplementation of selenium in left ventricular assist device implant surgery: A double‐blinded, randomized controlled pilot trial
Open Access
- 3 December 2021
- journal article
- research article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 46 (6) , 1412-1419
Abstract
Background : Systemic inflammation and oxidative stress remain the main cause of complications in heart failure patients receiving a left ventricular assist device (LVAD). Selenoproteins are a cornerstone of antioxidant defense mechanisms for improving inflammatory conditions. Methods : We conducted a monocentric double-blinded, randomized pilot trial. Patients scheduled for LVAD implantation were randomized to receive 300μg of selenium the evening before surgery orally, followed by high-dose intravenous selenium supplementation (3000μg after anesthesia induction, 1000 μg upon intensive care unit (ICU) admission, and 1000μg daily at ICU for a maximum of 14 days), or placebo. The main outcomes of this pilot study were feasibility and effectiveness in restoring serum selenium concentrations. Results : 20 out of 21 randomized patients were included in the analysis. The average recruitment rate was 1.5 patients/month (0–3). The average duration of study intervention was 12.6 days (7–14) with a 97.7% dose compliance. No patient received open-label selenium. The supplementation strategy was effective in compensating low serum selenium concentration (before surgery: control: 63.5±11.9μg/L vs. intervention: 65.8±16.5μg/L, ICU admission: control: 49.0±9.8μg/L vs. intervention: 144.2±45.4μg/L). Comparing to the control group, the serum selenium concentrations in the intervention group were significantly higher during the observation period (baseline: mean of placebo (MoP):63.1 vs. mean of selenium (MoS):64.0; ICU admission: MoP:49.0 vs. MoS:144.6; day 1:MoP:44.9 vs. MoS: 102.4; day 3: MoP:43.6 vs. MoS:100.4; day 5: MoP:48.5 vs. MoS:114.7; day 7: MoP:44.4 vs.MoS:118.3; day 13:MoP:48.0 vs. MoS:131.0). Conclusions : Selenium supplementation in patients receiving LVAD-implantation is feasible and effective to compensate a selenium deficiency. This article is protected by copyright. All rights reservedKeywords
This publication has 46 references indexed in Scilit:
- Lower whole blood selenium level is associated with higher operative risk and mortality following cardiac surgeryJournal of Anesthesia, 2012
- The intraoperative decrease of selenium is associated with the postoperative development of multiorgan dysfunction in cardiac surgical patients*Critical Care Medicine, 2011
- Selenium controls the sex-specific immune response and selenoprotein expression during the acute-phase response in miceBiochemical Journal, 2010
- Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trialThe American Journal of Clinical Nutrition, 2010
- Down‐regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in miceThe FASEB Journal, 2009
- Inflammatory response and cardioprotection during open‐heart surgery: the importance of anaestheticsBritish Journal of Pharmacology, 2008
- Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock*Critical Care Medicine, 2007
- Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart FailureNew England Journal of Medicine, 2006
- Assessment of requirements for selenium and adequacy of selenium status: a reviewEuropean Journal of Clinical Nutrition, 2004
- Possible role of increased oxidant stress in multiple organ failure after systemic inflammatory response syndromeCritical Care Medicine, 2003